首页> 外文期刊>Journal of endocrinological investigation. >Copeptin in the differential diagnosis of hypotonic polyuria
【24h】

Copeptin in the differential diagnosis of hypotonic polyuria

机译:Copeptin在低渗性多尿症鉴别诊断中的应用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Copeptin Copeptin is secreted in equimolar amount to Arginine Vasopressin (AVP) but can easily be measured with a sandwich immunoassay. Both peptides, copeptin and AVP, show a high correlation. Accordingly, copeptin mirrors the amount of AVP in the circulation and its measurement provides an attractive marker in the differential diagnosis of diabetes insipidus. The polyuria polydipsia syndrome Diabetes insipidus-either central or nephrogenic-has to be differentiated from primary polydipsia. Differentiation is crucial since wrong treatment can have deleterious consequences. Since many decades, the "gold standard" for differential diagnosis has been the classical water deprivation test, which has several limitations leading to an overall limited diagnostic accuracy. In addition, the test has a long duration of 17 hours and is cumbersome for patients. Clinical signs and symptoms as well as MRI characteristics overlap between patients with diabetes insipidus and primary polydipsia. Direct measurement of AVP upon osmotic stimulation was first shown to overcome these limitations, but failed to enter clinical practice mainly due to technical limitations of the AVP assay. Copeptin as diagnostic tool in the polyuria polydipsia syndrome We have recently shown that copeptin, without prior water deprivation, identifies patients with nephrogenic diabetes insipidus. On the other hand, for the more difficult differentiation between central diabetes insipidus and primary polydipsia, a copeptin level of 4.9 pmol/L stimulated with hypertonic saline infusion differentiates between these two entities with a high diagnostic accuracy, and is superior to the water deprivation test. It is important to note that close sodium monitoring during the hypertonic saline test is a prerequisite. Conclusion Therefore, we propose that copeptin upon hypertonic saline infusion should become the new standard test in the differential diagnosis of diabetes insipidus.
机译:Copeptin Copeptin 与精氨酸加压素 (AVP) 等摩尔分泌,但可以很容易地用夹心免疫测定法测量。肽(copeptin)和AVP两种肽都显示出高度相关性。因此,copeptin 反映了循环中 AVP 的量,其测量为尿崩症的鉴别诊断提供了有吸引力的标志物。多尿性烦渴综合征 尿崩症(中枢性尿崩症或肾性尿崩症)必须与原发性烦渴相鉴别。区分至关重要,因为错误的治疗可能会产生有害后果。几十年来,鉴别诊断的“金标准”一直是经典的禁水试验,它有几个局限性,导致总体诊断准确性有限。此外,该测试持续时间长达 17 小时,对患者来说很麻烦。尿崩症和原发性烦渴患者的临床体征和症状以及 MRI 特征重叠。渗透刺激后直接测量 AVP 首先被证明可以克服这些局限性,但主要由于 AVP 测定的技术局限性而未能进入临床实践。Copeptin 作为多尿多饮综合征的诊断工具 我们最近表明,在不事先禁水的情况下,copeptin可以识别肾性尿崩症患者。另一方面,对于更难鉴别的中枢性尿崩症和原发性烦渴,高渗盐水输注刺激的 4.9 pmol/L 的 copeptin 水平可鉴别这两种疾病,诊断准确性高,优于禁水试验。需要注意的是,在高渗盐水试验期间密切监测钠是先决条件。结论 因此,我们提出高渗盐水输注copeptin应成为尿崩症鉴别诊断的新标准。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号